TABLE 3.

Anti-cancer effects of HDAC inhibitors in HCC.

HDAC Inhibitor	Specificity	Effects in HCC	References
Panobinostat	Classes I, II, IV	inhibit HCC growth and metastasis	Song et al. (2013)
		decreased expression of an anti-apoptotic protein	(Choi et al., 2021)
		elicits effective responses to sorafenib	Lachenmayer et al. (2012)
Vorinostat (SAHA)	Classes I, II, IV	induce EMT	(Xu et al., 2018; Xiao et al., 2020)
		sensitize HCC cells to sorafenib	Yuan et al. (2014)
		sensitize HCC cells to 5-FU	Wang et al. (2021)
SAHA analogues	Classes I, II, IV	inhibits cell proliferation and induces apoptosis	Srinivas et al. (2016)
sodium butyrate	Classes I, II	induce EMT	(Xu et al., 2018; Xiao et al., 2020)
		suppresses HCC growth	Yang et al. (2017)
valproate (VPA)	Classes I, II	inhibits cell proliferation and induces apoptosis	Armeanu et al. (2005)
eicosapentaenoic acid	HDAC1	promotes tumor suppressor gene expression	Ceccarelli et al. (2020)
Santacruzamate A	HDAC2	increasing the sensitivity of radiotherapy	Jin et al. (2021)
Droxinostat	HDAC3	induces apoptosis	Liu et al. (2016b)
PCI-34051	HDAC8	elicits effective responses to ICB	Yang et al. (2021)
Rhamnetin	SIRT1	enhances the antitumor effect of sorafenib	(Li et al., 2021)